The FTSE 100 index has started the year well as it surged to a record high. It moved to a high of £8,645, up by over 75% from ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

Shell shares have risen 13p to 2608p as the promise of another $3.5 billion buyback offset a bigger-than-expected fall in ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) stock in focus as KKR (KKR) builds stake and the company posts its preliminary Q4 2024 financials. Read ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.